Patent ID: 9393330
Filing Date: 2016-07-19
CPC Classification: A61K,C07K,G01N

Claim Text:
1. A method of diagnosing the existence or absence of melanoma in a patient at risk for melanoma comprising administering to said patient a compound according to the chemical structure: Wherein Y is a chelate group which incorporates or is complexed with a radioisotope; Each X is independently an amino acid residue or an amino acid linker according to the chemical structure: ABC is an amino acid linker wherein A is absent or is a neutral or negatively charged amino acid at physiological pH; B is a neutral or negatively charged amino acid at physiological pH; C is absent or is a neutral or negatively charged amino acid at physiological pH; m is an integer from 0 to 3; n is 0 or 1; p is an integer from 0 to 20; q is 1, and Cycpeptide is a cyclic peptide comprising between 11 and 13 amino acids according to the structure: Wherein X is norleucine (Nle), leucine or isoleucine; Y Z is glycine or alanine; W is valine, leucine or isoleucine; T is aspartic acid, glutamic acid or a group; Where Z is an amino acid residue or an amino acid linker according to the chemical structure: j is 0, 1 or 2; r is an integer from 0 to 5; s is 1; w is 0 to 20; or a pharmaceutically acceptable salt thereof, and wherein said radioisotope is selected from the group consisting of imaging said patient after administration of said compound; and diagnosing said patient as having melanoma in tissue of said patient if said tissue evidences elevated binding of said compound in comparison to a normal standard.